Date: 2014-09-25
Type of information: Development agreement
Compound: emergency diagnostic tests
Company: AP-HP (France) Magnisense (France)
Therapeutic area: Cardiovascular diseases - Diagnostic
Type agreement: development
Action mechanism: The Magnisense emergency diagnostic tests combine a reader, software and consumables. The tests have been developed by using the proprietary technology of Magnisense, the MIAtek® technology. The MIAtek® technology is based on the use of nano-sized super paramagnetic particles. The technology is rising from interdisciplinary. The use of magnetic nanoparticles allows to precisely quantify a very small amount of biomarker directly in a very complex biological sample, in a very robust and simple way: superparamagnetism signal is not present in biological samples, is no time and temperature- dependent, is not affected by sample turbidity, colour or inhibitors. The technological breakthrough relies on the unique utilization of the magnetic signature of beads. When the biological reaction is finished after a few minutes, the consumable is placed in the multicoil reading head of the MIAtek® reader, which detects and counts the number of superparamagnetic particles specifically bound to the selected marker on the MIAstrip® line test. MIAtek® measures only the non-linear impact of superparamagnetic particles on the excitation magnetic field. Superparamagnetic beads are simultaneously excited by two oscillating currents with different frequencies (f0 & f1) The non-linearity of superparamagnetic materials causes an intermodulation between both frequencies and generates new spectral components in the spectrum of the measured voltage. These peaks are proportional to the volume of the superparamagnetic particles used as labels. MIAtek® technology is based on the measurement of these intermodulation peaks which permits a more accurate detection of the quantity of superparamagnetic labels. IV) The MIAtek® system delivers easy to read results on a smart man-machine interface which can be interconnected with centralized organizations. Thanks to the MIAtek® software, the concentration of the marker detected in the biological sample is given as a digital result on the screen of a smart connected interface, in a very easy way to read and stored. The system can be easily interconnected to Hospital Information System or Laboratories Information System through an adapted software and interface, to circulate and share results with centralized organizations.
Disease: cardiovascular diseases
Details: * On September 25, 2014, the Assistance Publique-Hôpitaux de Paris (AP-HP) and Magnisense have concluded a partnership agreement for the development of emergency diagnostic tests for cardiovascular diseases. As part of this partnership, the AP-HP allows Magnisense access to biological samples from valuable and unique cohorts patients with cardiovascular diseases and contributes to the validation testing. The AP-HP also grants Magnisense a commercial operating license option agreement exclusive worldwide one of their patents on postpartum hemorrhage in women (Nouveau procédé de pronostic associé aux cas d’hémorragie post-partum » WO2010015690 A1 - Inventeurs : A. Mebazaa, E. Gayat, M. Resche Rigon, M. Rossignol, O. Morel, Y. Fargeaudou et D. Payen). Magnisense and the team of Professor Alexandre Mebazaa cooperate to develop and register new emergency tests for myocardial infarction that meet emergency physicians, anesthetists and cardiologists\'s expectations: robust, portable, economical, connected and quantitative tests on blood total in 15 minutes. These tests are performed with the instrument designed by the company Magnisense, using its proprietary technology MIAtek®. The goal of the company is to market Magnisense its first tests in France in the coming months, then in Europe and the rest of the world. In parallel, the same tests can be registered and marketed for the \"prediction of postpartum hemorrhage in women\", one of the leading causes of death after childbirth. These tests, which combine to establish a predictive risk score of postpartum hemorrhage, as has been demonstrated by the pioneering work of Professor and Dr. Mebazaa Gayat.
Financial terms:
Latest news:
